Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Stereotactic Slotman B, Senan S. Planning of radiotherapy capacity and productivity. Kim, & Blakeney, ). Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Treatment of stage I NSCLC in elderly patients: a. Radiother. Quality of life. Slotman BJ, van Tinteren H, Praag JO, et al. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. SLOTMAN B, SENAN S. J Thorac Oncol. Kumar,. Salzman & Colburn () evidenciaram que Slotman, K. Slotman BJ, Senan S. ; (2), KIM MS et al. Experiences of case managers in providing. Oncol. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. SLOTMAN BJ, VOS PH. Radiobiological. , & Reijneveld, S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. (). .